Clinical Trial Update: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [Phase 1]

View source ↗

Summary

Phase 1 study of Veliparib with Topotecan, with or without Carboplatin, in relapsed or refractory acute leukemias, high-risk myelodysplastic syndromes, and aggr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Erythroleukemia
• Essential Thrombocythemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Polycythemia Vera
• Pure Erythroid Leukemia

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Topotecan (topotecan)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 1 | Status: COMPLETED